Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
A Sanofi executive said the company will "shoulder the cost" of any adverse events that are scientifically linked to vaccination.
As investigations in the Philippines proceed, Sanofi Pasteur has agreed to refund the cost of unused Dengvaxia doses worth about $28 million.
BMS’s Opdivo is the only immuno-oncology drug approved to treat kidney cancer, but more rivals are threatening that status.
Following mass immunization program halt, Dengvaxia’s marketing authorization in the Philippines has been put on hold for a year.
Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.
Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.
A Sanofi exec defended its dengue shot in the Philippines on Monday as new reports showed local experts had warned against a broad vaccination push.
The Philippines halted its dengue vaccination program after Sanofi flagged serious risks for recipients who'd never been infected with the virus.
Russian biotech Biocad said it reached a deal with Sothema Labs of Morocco to produce biosimilars rituximab and bevacizumab, used to treat cancer.
Gilead is introducing Sovaldi in China, where it faces mounting competitive pressure, at a steep discount.